In a recent article published in Nutrients, researchers investigated the current evidence of the impact of milk oligosaccharides (MOS) on early life neurocognitive and brain development.
Dyne Therapeutics sharpens case for two muscle disease therapies with updated data
Dyne Therapeutics shared promising clinical trial updates from two of its experimental RNA medicines for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy. The